Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$124.00

-2.57 (-2.03%)

09:00
03/25/19
03/25
09:00
03/25/19
09:00

Sarepta data bode well for registration study, says H.C. Wainwright

The functional gains with Sarepta Therapeutics' SRP-9001 in this morning's data bode well for the registration study, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. Micro-dystrophin gene therapy appears to positively impact key functional endpoints with a 34% increase in NSAA scores, and a -20%, -29%, and -13% change in time to rise, four-minute stair climb, and time to 100 meters, respectively from baseline to day 270, says the analyst. While bears are likely to point to the large variability in CK, a 64% decline from baseline, while not quite the 90%-plus at an earlier time point, for a measurement that is uniquely susceptible to activity is more an attribute of increased functional capacity as opposed to waning of gene therapy's effectiveness hypothesis in the younger patients, contends Chattopadhyay. He has a Buy rating on Sarepta with a $267 price target.

  • 25

    Mar

  • 19

    Aug

SRPT Sarepta
$124.00

-2.57 (-2.03%)

03/06/19
PIPR
03/06/19
NO CHANGE
Target $200
PIPR
Overweight
Sarepta selloff on short report a buying opportunity, says Piper Jaffray
A short report on Sarepta Therapeutics was published this morning and appears to be the reason for today's selloff, Piper Jaffray analyst Danielle Brill tells investors in a research note. After going through the report, however, the analyst found "no salient points to consider," and she remains confident in her Overweight thesis on the shares. The LGMD-2E data presented last week sufficiently demonstrated proof-of-concept and further de-risked Sarepta's muscle targeted gene therapy platform, says Brill. She believes the company's fundamentals remain intact and would be a buyer on today's selloff. The analyst reiterates an Overweight rating on Sarepta with a $200 price target. The stock in midday trading is down 9%, or $13.21, to $135.38. The short report, while not mentioned by name in Piper's research note, is said to be from Elliot Favus of Favus Institutional Research. In addition, a secondary offering of 2.6M Sarepta shares priced last night at $144.00.
03/07/19
CANT
03/07/19
NO CHANGE
Target $231
CANT
Overweight
Sarepta sees slight bounce back after Cantor calls selloff unwarranted
Shares of Sarepta Therapeutics are bouncing back slightly following yesterday's 11% selloff. The weakness yesterday stemmed from Tuesday's night capital raise as well as the resignation of FDA Commissioner Scott Gottlieb, and, to a lesser extent, a new short report, Cantor Fitzgerald analyst Alethia Young told investors last night in a research note. On the short report, the analyst disagrees with her understanding of its key points, and particularly thinks increasing the betasarcoglycan protein will lead to functional change over time. Sarepta has a clear lead in Duchenne muscular dystrophy gene therapy and its data has set a high bar for competition, Young wrote. Further, she thinks that if demand is available and companies can get capital they do. As such, the analyst is unconcerned by Tuesday's equity raise. As it relates to Dr. Gottlieb's departure, Young notes that Dr. Woodcock, who has been supportive of DMD, is still at the agency. All today, the analyst views yesterday's selloff as unwarranted and reiterated Sarepta as one of her top 2019 picks. She has an Overweight rating on the shares with a $231 price target. Sarepta in late morning trading is up 2%, or $2.38, to $134.63.
03/11/19
FBCO
03/11/19
NO CHANGE
Target $207
FBCO
Outperform
Sarepta price target raised to $207 from $189 at Credit Suisse
Credit Suisse analyst Martin Auster maintained an Outperform rating on Sarepta (SRPT) and raised his price target to $207 from $189. In a research note to investors, Auster says his bull thesis has strengthened further, and that he is growing increasingly comfortable that the company's Duchenne Muscular Dystrophy program may provide to be first-in-class as well as best-in-class. He sees the completion of Sarepta's manufacturing scale-up allowing for commencement of the confirmatory Phase 3 trial in late 2019 and initial Phase 1/2 data from Pfizer (PFE) in its DMD gene tx trial in Q3 as critical catalysts to drive share appreciation of the next nine months.
03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.

TODAY'S FREE FLY STORIES

PICO

PICO Holdings

$10.81

0.31 (2.95%)

17:45
12/06/19
12/06
17:45
12/06/19
17:45
Hot Stocks
PICO Holdings sells long-term storage credits for $8.7M in Arizona »

PICO Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QHC

Quorum Health

$0.95

0.0522 (5.81%)

17:31
12/06/19
12/06
17:31
12/06/19
17:31
Hot Stocks
Quorum Health receives NYSE continued listing standard notice »

Quorum Health Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:30
12/06/19
12/06
17:30
12/06/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.69

0.34 (5.35%)

17:29
12/06/19
12/06
17:29
12/06/19
17:29
Syndicate
Breaking Syndicate news story on Baudax Bio »

Baudax Bio files $125M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

LMT

Lockheed Martin

$387.10

1.175 (0.30%)

17:25
12/06/19
12/06
17:25
12/06/19
17:25
Hot Stocks
Lockheed Martin awarded $153.39M Navy contract modification »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENV

Envestnet

$71.72

1.27 (1.80%)

17:23
12/06/19
12/06
17:23
12/06/19
17:23
Syndicate
Breaking Syndicate news story on Envestnet »

Envestnet files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$344.79

0.4 (0.12%)

17:20
12/06/19
12/06
17:20
12/06/19
17:20
Hot Stocks
Northrop Grumman awarded $189M Navy contract modification »

Northrop Grumman was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:03
12/06/19
12/06
17:03
12/06/19
17:03
Hot Stocks
Support.com announces special distribution of $1.00 per share »

The record date for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:01
12/06/19
12/06
17:01
12/06/19
17:01
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RZLT

Rezolute

$0.00

(0.00%)

17:00
12/06/19
12/06
17:00
12/06/19
17:00
Syndicate
Breaking Syndicate news story on Rezolute »

Rezolute files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

16:58
12/06/19
12/06
16:58
12/06/19
16:58
Periodicals
U.S. mulls putting Amazon foreign sites on 'Notorious Markets' list, WSJ says »

The Trump administration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

16:55
12/06/19
12/06
16:55
12/06/19
16:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

IMH

IMPAC Mortgage

$5.63

-0.01 (-0.18%)

16:54
12/06/19
12/06
16:54
12/06/19
16:54
Syndicate
Breaking Syndicate news story on IMPAC Mortgage »

IMPAC Mortgage files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALEC

Alector

$19.74

0.33 (1.70%)

16:32
12/06/19
12/06
16:32
12/06/19
16:32
Hot Stocks
Alector reports Phase 1 safety, biomaker data on AL002 »

Alector reported safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATAX

America First Multifamily Investors

$7.58

0.125 (1.68%)

16:31
12/06/19
12/06
16:31
12/06/19
16:31
Hot Stocks
America First Multifamily Investors CFO Craig Allen to retire »

On December 2,Craig Allen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
12/06/19
12/06
16:30
12/06/19
16:30
Options
Preliminary option volume of 20.4M today »

Preliminary option volume…

PNM

PNM Resources

$48.77

-0.06 (-0.12%)

16:29
12/06/19
12/06
16:29
12/06/19
16:29
Hot Stocks
PNM Resources raises quarterly dividend 6% to 30.75c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MORN

Morningstar

$154.47

-0.25 (-0.16%)

16:22
12/06/19
12/06
16:22
12/06/19
16:22
Hot Stocks
Morningstar raises quarterly dividend 7.1% to 30c from 28c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACEL

Alfacell Corporation

$11.11

0.1 (0.91%)

16:22
12/06/19
12/06
16:22
12/06/19
16:22
Hot Stocks
Crescent Park Management reports 6.4% passive stake in Accell »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

O

Realty Income

$75.96

0.31 (0.41%)

16:21
12/06/19
12/06
16:21
12/06/19
16:21
Syndicate
Breaking Syndicate news story on Realty Income »

Realty Income files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
12/06/19
12/06
16:20
12/06/19
16:20
Options
Closing CBOE SPX and VIX Index summary for December 6th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:19
12/06/19
12/06
16:19
12/06/19
16:19
Hot Stocks
Bristol-Myers, Bluebird Bio: Phase 2 KarMMa study of ide-cel met endpoints »

Bristol-Myers Squibb…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UBER

Uber

$27.87

-0.775 (-2.71%)

, ALXN

Alexion

$113.86

6.44 (6.00%)

16:18
12/06/19
12/06
16:18
12/06/19
16:18
On The Fly
Fly Intel: Wall Street's top stories for Friday »

For the first day in what…

UBER

Uber

$27.87

-0.775 (-2.71%)

ALXN

Alexion

$113.86

6.44 (6.00%)

MMM

3M

$171.43

7.07 (4.30%)

ICE

IntercontinentalExchange

$93.81

0.17 (0.18%)

TTD

Trade Desk

$247.63

7.36 (3.06%)

BIG

Big Lots

$25.22

6.05 (31.56%)

ULTA

Ulta Beauty

$262.19

26.1 (11.06%)

CIEN

Ciena

$35.01

-1.29 (-3.55%)

PD

PagerDuty

$21.81

-3.185 (-12.75%)

YEXT

Yext

$14.26

-2.355 (-14.17%)

ZM

Zoom Video

$62.76

-6.97 (-10.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 16

    Dec

  • 12

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
12/06/19
12/06
16:17
12/06/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLEX

Lilis Energy

$0.16

-0.0015 (-0.92%)

16:16
12/06/19
12/06
16:16
12/06/19
16:16
Hot Stocks
Lilis Energy discloses notice of NYSE listing deficiency »

Lilis Energ received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.